Most adults who meet this test meet it for one of two reasons. Either an androgen marker came back higher than expected, or cycles, skin and hair growth changed in a way that needs explaining. This page walks through what the marker measures, how timing changes the number, what high and normal results may reflect, and what a clinician usually does next.
No. Progesterone and 17-hydroxyprogesterone are two different molecules with two different jobs, even though their names sit a syllable apart.
Progesterone is the hormone the corpus luteum releases after ovulation. It is measured mainly to confirm that ovulation happened and to read the second half of the cycle. 17-OHP is a precursor further along the steroid assembly line, and it is measured mainly to ask whether the adrenal glands are building cortisol efficiently.
A lab will not substitute one for the other, and a normal progesterone value says nothing useful about 17-OHP. If you arrived here looking for the ovulation marker, the Progesterone guide linked above covers what it measures, how it is tested and how to read a result. The rest of this page stays with 17-OHP.
17-OHP is a waypoint rather than a destination. It is an intermediate on the route from cholesterol to cortisol, and at usual concentrations it does very little hormonal work of its own.
The outer layer of the adrenal gland converts cholesterol to pregnenolone, then through 17-hydroxypregnenolone to 17-OHP. From there an enzyme called 21-hydroxylase converts 17-OHP into 11-deoxycortisol, which becomes cortisol one step later. The pituitary gland watches the cortisol output and releases ACTH to keep it steady. If any step on the path runs slowly, cortisol output lags, ACTH rises to push harder, and the molecule sitting immediately upstream of the slow step accumulates. That is why 17-OHP behaves like a pressure gauge on the pathway.
The adrenal glands are not the only source. In people who ovulate, the corpus luteum produces 17-OHP during the second half of the cycle, so a sample drawn after ovulation reads higher than one drawn in the first week. The testes produce a smaller amount. Adrenal output also follows the daily ACTH rhythm, running highest in the early morning and drifting down across the day.
Two practical consequences follow. First, a 17-OHP value is only interpretable when you know when it was drawn, both the hour and the cycle day. Second, a single raised number is a question, not an answer, because normal physiology can produce one.
It matters because a persistently raised 17-OHP is the main biochemical clue to nonclassic congenital adrenal hyperplasia, a mild form of the condition that often goes unrecognised until adulthood 1. In adults the picture is usually subtle rather than severe.
Studies indicate that in adolescent and adult women the common presenting features are excess hair growth in a male pattern, persistent acne, irregular or absent periods, and difficulty conceiving 2. None of those features is specific on its own, which is exactly why a precursor measurement is useful. It separates an adrenal enzyme bottleneck from the other reasons androgen-driven signs appear.
There is a second reason the marker earns its place on a panel. When androgen markers are elevated, a clinician needs to know roughly where the extra androgen is coming from, because adrenal and ovarian sources behave differently over time. 17-OHP is one of the cheapest ways to ask that question. In men, the marker is ordered far less often, and it is read alongside the rest of the adrenal picture rather than on its own.
17-OHP is usually reported in nanograms per decilitre (ng/dL) or nanomoles per litre (nmol/L), and the normal window depends heavily on sex, cycle phase and the hour of the draw.
| Group and timing | Typical lab reference range (17-OHP) |
|---|---|
| Adult women, follicular phase, early morning | roughly under 80 ng/dL (about 2.4 nmol/L) |
| Adult women, luteal phase | higher, commonly up to roughly 285 ng/dL (about 8.6 nmol/L) |
| Adult men | roughly 30 to 200 ng/dL (about 0.9 to 6 nmol/L) |
| Women after menopause | roughly under 50 ng/dL (about 1.5 nmol/L) |
These are typical lab reference ranges, and they vary by lab, assay, age and sex. Always read the range printed on your own report rather than one from the internet, because two labs can flag the same raw value differently.
For screening purposes there is a widely used decision point rather than a simple in-or-out range. Research suggests that an early morning, follicular-phase 17-OHP below roughly 200 ng/dL (about 6 nmol/L) makes nonclassic congenital adrenal hyperplasia unlikely, while values above that threshold usually prompt a stimulated test rather than a diagnosis 2.
Assay method matters too. Older immunoassays can cross-react with structurally similar steroids and read artificially high, so many labs confirm raised values with mass spectrometry. If you are comparing a result from one lab with a result from another, check the method and the units before concluding that anything has changed.
A high 17-OHP means the pathway is backing up at that moment, and the honest first question is whether the sample was drawn in a way that would produce a high number anyway.
The common explanations are, in rough order of frequency, a sample taken after ovulation rather than in the first week of the cycle, a sample taken later in the day when adrenal rhythms are less informative, an assay cross-reaction, and pregnancy, where placental and fetal steroid production raises the baseline. After those are excluded, a persistently raised morning follicular value is the pattern that points toward partial 21-hydroxylase deficiency 1.
Much less often, a markedly raised value reflects another enzyme difference in the same pathway, or an adrenal growth producing steroid precursors. Those are uncommon, and they are not conclusions you can reach from one number on a portal.
So the sequence is: observe the value and the conditions it was drawn under, consider what it may reflect, then take the next step with a clinician. A mildly raised result in the luteal phase is usually a repeat test at the right time. A substantially raised morning value, especially alongside rapidly worsening androgen-driven signs, is worth discussing with a clinician promptly rather than at the next routine visit. A raised 17-OHP on its own is suboptimal information, not a diagnosis, and it never means you should ignore the result either.
A morning, follicular-phase value inside the reference range makes an adrenal enzyme bottleneck a much less likely explanation for androgen-driven symptoms, which is the main thing the test is there to do.
That is useful negative information. It does not say the symptoms are imaginary, and it does not rule out every cause of irregular cycles, acne or excess hair growth. It narrows the field, which is how most screening markers earn their keep. Symptoms still need an explanation, and the search simply moves elsewhere, usually toward ovarian androgen production, insulin and metabolic markers, thyroid function, or the other adrenal steroids.
There is one timing caveat worth repeating. A normal value drawn at 4pm, or drawn a week after ovulation, carries much less weight than a normal value drawn before 8am in the first few days of a cycle. If the sample was taken at a convenient time rather than the right time, a normal result is reassuring but not definitive, and a repeat under proper conditions is a reasonable thing to ask about.
A genuinely low 17-OHP is rarely acted on by itself. Values at the bottom of the range are usually read as part of a wider adrenal picture, alongside cortisol and ACTH, rather than treated as a finding in isolation.
Nonclassic congenital adrenal hyperplasia (NCCAH) is a mild, inherited partial deficiency of the 21-hydroxylase enzyme, which slows the conversion of 17-OHP toward cortisol and allows precursors to spill toward androgen production 1.
Unlike the classic form, which is severe and identified in infancy, the nonclassic form leaves enough enzyme activity for cortisol production to stay adequate under normal conditions. The visible consequence is not adrenal failure, it is a modest excess of adrenal androgens over years. Research suggests that presentation ranges widely, from no symptoms at all to early pubic hair in childhood, and in adults to hirsutism, acne, menstrual irregularity and reduced fertility 4.
Because the enzyme activity is only partly reduced, the biochemical signal is partial too. That is the single most important thing to understand about reading 17-OHP in adults. A person with NCCAH may have a clearly raised morning value, or a borderline one that only declares itself after stimulation.
It is inherited in an autosomal recessive pattern, meaning both copies of the gene carry a change, usually one from each parent. That is why family history sometimes makes sense in hindsight, and why genetic counselling can become part of the conversation once a diagnosis is confirmed. None of this is decided by a biomarker alone. A clinician combines the biochemistry, the symptoms and, where appropriate, genetic testing.
It is a standard venous blood draw, and timing matters more for this marker than for almost any other hormone on a general panel.
Three rules cover most situations. Draw it in the early morning, ideally before 8am, when adrenal output is at its daily peak and a normal result is most meaningful. In people who are cycling, draw it in the follicular phase, commonly days 3 to 5 counted from the first day of full flow, before the corpus luteum starts contributing. And draw it under ordinary conditions rather than during an acute illness, when the whole adrenal axis is running differently.
Fasting is not usually required for 17-OHP itself, though it may be required for other markers drawn at the same appointment, so follow the instructions on your requisition. Tell the ordering clinician about every medication and supplement you take, including anything hormonal, because several can shift adrenal or gonadal steroid readings and change how your result should be read.
When a baseline value lands in the grey zone, the next investigation is a stimulated test. A clinician gives a short adrenal stimulus in a supervised setting and measures how far 17-OHP rises over the following hour, which separates a mild enzyme bottleneck from normal variation better than a single resting value can 2. That test is arranged and interpreted by a clinician, not ordered as a self-serve add-on.
Plenty, which is why the same person can produce two very different numbers in the same month without anything changing inside them.
The main movers are time of day, cycle phase, pregnancy, acute physical stress or illness, and the assay used. Age shifts the picture too, since baseline values differ in the years around and after menopause. Laboratory handling plays a quiet role as well. Samples that sit before processing, or that are run on different platforms, do not always agree closely.
Some medications affect adrenal and gonadal steroid output or interfere with the measurement itself. This page does not name them, because whether any of them is relevant to your result depends on your history and is a question for the clinician who ordered the test. The practical move is to bring a complete list to the appointment rather than to guess.
What does not move 17-OHP meaningfully is day-to-day diet, a single poor night of sleep, or a hard training session the day before, at least not to a degree that changes interpretation. The marker is driven by enzyme capacity and by the ACTH rhythm, not by lifestyle noise. That is a useful property. It means a confirmed, properly timed, repeatedly raised value is a real signal rather than an artefact of how last week went.
17-OHP is close to uninterpretable in isolation, so it is almost always read as part of an adrenal and androgen group.
The usual companions are cortisol, which is the hormone the whole pathway exists to produce, DHEA-S, which is the clearest single read on adrenal androgen output, and total testosterone, which in women is used as an androgen read rather than as anything to do with replacement therapy. Androstenedione, SHBG, LH and FSH often join them, since they help separate an adrenal source from an ovarian one. ACTH is sometimes added when the question is how hard the pituitary is pushing the adrenal glands.
Progesterone itself is sometimes measured at the same time, usually to establish where in the cycle the sample sits.
| Marker and group | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Progesterone, women | 1 to 25 ng/mL | 5 to 20 ng/mL |
| Progesterone, men | 0.1 to 2 ng/mL | 0.2 to 1.4 ng/mL |
Optimal ranges here are optimization targets, not diagnostic cut-offs, and the typical ranges shown vary by lab, age and sex. Patterns across this group carry more information than any single value. Raised 17-OHP with raised DHEA-S points at the adrenal glands. Raised testosterone with a normal morning follicular 17-OHP points elsewhere. That is the kind of read a clinician does with the whole panel in front of them.
The overlap is substantial, and distinguishing the two is one of the main clinical reasons the test gets ordered in the first place.
Irregular cycles, acne, excess hair growth, raised androgen markers and difficulty conceiving appear in both conditions, and studies indicate that nonclassic congenital adrenal hyperplasia in women is regularly mistaken for polycystic ovary syndrome because the presentations are so similar 2. Ultrasound does not reliably separate them either, since polycystic-appearing ovaries can occur in both.
That is why a morning follicular 17-OHP is commonly included in the workup of androgen excess. It is a cheap, specific question aimed at one of the few causes that has a different underlying mechanism and different implications for family planning.
For the reader, the practical point is simple. A previous diagnosis of polycystic ovary syndrome made without a 17-OHP measurement is not wrong, but it was made without one of the checks that separates the two. If androgen-driven symptoms persist, asking whether that marker has ever been drawn at the right time of day and the right point in the cycle is a reasonable question to put to your clinician.
The usual next step is a repeat measurement under properly controlled conditions, followed, if the value stays raised, by a stimulated test rather than an immediate diagnosis.
A clinician will first check whether the original sample was drawn in the early morning and in the follicular phase, and whether pregnancy or an interfering assay could explain the number. If the repeat sits clearly in the grey zone, the stimulated test measures the 17-OHP response rather than the resting level, which is the more discriminating measurement for a partial enzyme deficiency 2.
Genetic testing of the relevant gene is sometimes added, particularly where the biochemistry is ambiguous or where family planning decisions depend on knowing the exact variant.
It is worth being clear about who decides what. The sequence of tests, the interpretation and any decision about ongoing care belong to a licensed provider who has reviewed your history, your examination and your full panel. FitScript's membership includes 150+ biomarkers tested per year with interpretation by Atlas, its AI health advisor, and any treatment decision is made by a licensed provider after reviewing the member. A marker guide like this one tells you what the number is and what it may reflect. It cannot tell you what is happening in your body.
Less than most people expect, because the nonclassic form is mild by definition and care is tailored to symptoms rather than applied automatically.
Research suggests that not everyone with nonclassic congenital adrenal hyperplasia requires ongoing therapy, and that decisions depend on age, symptoms and personal goals at that point in life 5. Some people are monitored. Others are managed actively for a period and then reassessed. Those decisions sit entirely with a licensed provider who evaluates whether any given option is appropriate, and this page deliberately does not name or describe any of them.
Priorities also shift over time. Studies indicate that for females with the nonclassic form, the concerns that matter change across the move into adulthood, from early androgen-related signs toward cycle regularity, skin and hair, and questions about conceiving 6. Care that fits a teenager does not necessarily fit the same person a decade later.
Ongoing management is not always straightforward. Research suggests that symptoms, biochemical markers and a person's own goals do not always move in step, which is why follow-up is individualised rather than protocol-driven 7. In practice this means periodic review with a clinician who knows the condition, repeat markers at sensible intervals, and honest conversations about which symptoms actually bother you.
Speak to a clinician whenever a 17-OHP result sits outside the range printed on your report, and sooner if androgen-driven changes are progressing quickly.
The situations worth raising without waiting are rapidly worsening hair growth in a male pattern, periods that stop or become markedly irregular, new scalp hair thinning, acne that resists everything you have tried, or difficulty conceiving after a reasonable interval of trying. Any of these alongside a raised 17-OHP is worth discussing with a clinician promptly, not because a single value diagnoses anything, but because the combination deserves a proper workup rather than another year of waiting.
Bring the practical details with you, since they change the interpretation more than the number itself does. The time of the draw, the cycle day, the lab and assay used, any pregnancy, and a complete list of medications and supplements. A clinician can do far more with a properly contextualised borderline value than with a dramatic one drawn at the wrong hour.
This page is educational and not medical advice. Discuss your results, and any decision about care, with a clinician or licensed provider who can see your full history.
Related guides worth reading next: cortisol, the hormone this entire pathway is built to produce, dhea s, the clearest single read on adrenal androgen output, and testosterone total, which in women is interpreted as an androgen marker rather than anything to do with replacement.
It measures 17-hydroxyprogesterone, a steroid your adrenal glands and gonads make on the route to cortisol. Because it sits just upstream of a key enzyme step, the level reflects how smoothly that pathway is running. It is used mainly as a screen for congenital adrenal hyperplasia in people with androgen-related symptoms.
No. They are different molecules with different uses. Progesterone is measured mainly to confirm ovulation and read the luteal phase, while 17-OHP is measured to ask how efficiently the adrenal glands are producing cortisol. A normal progesterone result tells you nothing about 17-OHP.
Early in the morning, ideally before 8am, when adrenal output is at its daily peak. If you have menstrual cycles, the sample should usually be taken in the follicular phase, commonly days 3 to 5 from the first day of full flow. A sample drawn in the afternoon or after ovulation is much harder to interpret.
Fasting is not usually required for 17-OHP itself. Other markers drawn at the same appointment may require it, so follow the instructions printed on your requisition. Timing of day and cycle phase matter far more for this marker than whether you have eaten.
The most common reasons are a sample drawn after ovulation, a sample drawn later in the day, pregnancy, and cross-reaction in older laboratory assays. Acute illness can also shift adrenal readings. This is why a single high value is almost always repeated under properly controlled conditions before anything is concluded.
A clinician will usually repeat the test at the right hour and the right point in the cycle. If it stays raised, the next step is typically a supervised stimulation test that measures how the level responds rather than where it sits at rest. Genetic testing is sometimes added when the picture is still unclear.
Yes, although it is ordered far less often in men because the symptoms that prompt it are less visible. When it is measured, it is read alongside the rest of the adrenal and androgen picture rather than on its own. Timing of the draw still matters, since adrenal output follows a daily rhythm.
A properly timed morning, follicular-phase result inside the range makes an adrenal enzyme bottleneck much less likely, which is the main job of the test. It does not explain away ongoing symptoms, and it does not rule out other causes of irregular cycles, acne or excess hair growth. Those questions move to other markers and to your clinician.